Lake Street assumed coverage of Avita Medical (RCEL) with a Buy rating and a price target of $8, down from $14. Although guidance was cut materially, the company reiterated confidence in a second half recovery and the firm views this as “a prudent reset rather than a structural impairment,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL: